Codex Labs Highlights Published Research Examining Skin Barrier Function in Atopic Dermatitis
REDWOOD CITY, Calif., July 23, 2026 — Codex Labs Corporation today highlighted a growing body of published scientific research examining the role of skin barrier function in atopic dermatitis, commonly known as eczema. The company said the research reflects increasing scientific interest in understanding how skin barrier integrity may influence disease management alongside established clinical approaches.
Atopic dermatitis affects millions of people worldwide and is characterized by chronic inflammation, dry skin, and recurrent flare-ups. While treatment options vary depending on disease severity, researchers continue to investigate biological mechanisms that contribute to skin barrier dysfunction and their potential role in future therapeutic strategies.
Among the areas receiving significant attention is filaggrin, a naturally occurring protein involved in maintaining skin barrier structure and hydration. Published research has associated reduced filaggrin expression with impaired barrier function and increased susceptibility to environmental irritants. Scientists continue to study how these biological pathways contribute to the development and progression of atopic dermatitis.
Codex Labs stated that its research activities have focused on skin barrier biology, microbiome science, and biotechnology-derived botanical ingredients. According to the company, its scientists have developed proprietary technologies intended to support ongoing research in these fields and have secured multiple U.S. patents related to formulation technologies.
The company also referenced several peer-reviewed publications evaluating skin barrier science and related biological mechanisms. According to Codex Labs, the studies contribute to the broader scientific literature examining approaches that support healthy skin barrier function. Company representatives noted that independent scientific evaluation and continued research remain important components of advancing dermatological knowledge.
“Understanding the biological mechanisms involved in skin barrier function continues to be an important area of dermatology research,” said Dr. Barbara Paldus, Founder and Chief Executive Officer of Codex Labs. “Our objective is to contribute scientific research that expands understanding of skin biology while supporting continued investigation through peer-reviewed publication.”
Codex Labs also noted that additional research examining skin barrier biology remains underway and that future findings will be submitted for independent peer review as studies are completed.
Independent experts have increasingly recognized skin barrier restoration as an important area of investigation within dermatology. Researchers continue to evaluate how advances in microbiome science, skin physiology, and biotechnology may contribute to future innovations in skincare and dermatological research.
The company stated that it intends to continue collaborating with researchers and scientific institutions to expand understanding of skin barrier biology and related areas of dermatological science.
About Codex Labs
Codex Labs Corporation is a Silicon Valley biotechnology company focused on research involving skin biology, microbiome science, and biotechnology-derived botanical ingredients. The company develops technologies and conducts scientific research related to skin health and publishes research through scientific and peer-reviewed channels.
Media Contact
Media Relations
Codex Labs Corporation
Email: press@codexlabscorp.com
Phone: +1 650-400-4798
Website: www.codexlabscorp.com